

CANCER GENOMICS & PROTEOMICS

Published by the International Institute of Anticancer Research

ISSN (print): 1109-6535; ISSN (online): 1790-6245

Volume 8, 2011

INDEX

This volume is dedicated to the memory of
ANGELICA BURGER

Editorial Board

- A. Seth** Editor-in-Chief
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
- J.G. Delinassios** Managing Editor and Executive Publisher
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland
R. Abagyan The Scripps Research Institute, La Jolla, CA, USA
F. Ahmed Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA
S. Antonarakis Division of Medical Genetics, University of Geneva Medical School, Switzerland
D.-T. Bau Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan
A.M. Burger Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
M.R. Chance Case Western Reserve University, Center for Proteomics and Bioinformatics, Cleveland, OH, USA
A.M. Chinnaiyan Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
B.F.C. Clark Department of Molecular Biology, University of Aarhus, Denmark
R. Clarke Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
N. E. Davidson University of Pittsburgh, Cancer Institute, Pittsburgh, PA, USA
I. Dunham European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge, UK
T. Efferth Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Germany
J.A. Fernandes-Pol Metalloproteomics, LLC, Chesterfield, MO, USA
C.V. Forst Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA
M. Fountoulakis F. Hoffman-La Roche Pharmaceutical Research, Basel, Switzerland
D.S. Gerhard NIH / NCI, Office of Cancer Genomics, Bethesda, MD, USA
J.W. Gray OHSU Knight Cancer Institute, Biomedical Engineering, Portland, OR, USA
B.B. Haab Van Andel Research Institute, Grand Rapids, MI, USA
C.-H. Heldin Ludwig Institute for Cancer Research, Uppsala, Sweden
J.D. Hoheisel Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
R.P. Huang RayBiotech, Inc., Norcross, GA, USA
T.H.M. Huang Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA
S.C. Jhanwar Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
V.C. Jordan Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, USA
J. Ju Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
A. Kallioniemi Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
O.P. Kallioniemi Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
K. Khaili College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
- D.G. Kieback** Department of Obstetrics and Gynecology, Elblandklinikum, Riesa (Dresden), Germany
S.D. Kottaridis Department of Virology, Hellenic Anticancer Institute, Athens, Greece
B. Léyland-Jones Winship Cancer Center, Emory University School of Medicine, Atlanta, GA, USA
P. Lichter Deutsches Krebsforschungszentrum, Heidelberg, Germany
A. Lindblom Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
G. Lubec Department of Pediatrics, University of Vienna, Austria
J. Lyons-Weiler Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA
P.J. McCormick The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
- J.D. Minna** Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA
F. Mitelman Department of Clinical Genetics, University Hospital, Lund, Sweden
P. Nelson Fred Hutchinson Cancer Research Center, Seattle, WA, USA
C. Nicot Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA
- L. O'Driscoll** School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
I. Pastan Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA

C.D. Platsoucas	College of Sciences, Old Dominion University, Norfolk, VA, USA
J. Quackenbush	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
J.S. Rader	Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
A. Raouf	Department of Immunology, University of Manitoba, Manitoba Institute of Cell Biology (MICB), Winnipeg, MB, Canada
G. Rasty	Department of Anatomic Pathology, University Health Network, University of Toronto, Toronto, ON, Canada
G. Rechavi	Pediatric Hemato-Oncology Department, Sheba Medical Center, Tel-Hashomer, Israel
R.H. Reeves	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
K.L. Reichelt	Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
T. Ried	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
G. Rimbach	Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
K.D. Rodland	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
Y. Sakaki	Toyohashi University of Technology, Toyohashi, Japan
C. Sansom	The School of Crystallography, Birbeck College, University of London, UK
N.A. Saunders	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
J. Schneider	Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain
O.J. Semmes	Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
G.V. Sherbet	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
K.K. Singh	University of Alabama at Birmingham, Department of Genetics/Cancer Research, Birmingham, AL, USA
S. Smith	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
J.C. Strefford	Cancer Science Division, Southampton General Hospital, Southampton, UK
J.M. Trent	Tgen, Phoenix, AZ, USA
G. Tsangaris	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
L.-C. Tsui	University of Hong Kong, Hong Kong
G.F. Vande Woude	Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA
D.K. Watson	Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
K. Williams	Keck Laboratory, Department of Molecular Biophysics and Biochemistry, New Haven, CT, USA
A.T. Yeung	Fox Chase Cancer Center, Philadelphia, PA, USA
H. Zhang	Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; Science Citation Index; Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office:

International Institute of Anticancer Research
 1st km Kapandritiou-Kalamou Road,
 P.O. Box 22, Kapandriti, Attiki, 19014, Greece.
 Tel: +30 22950 52945, Fax: +30 22950 53389
 e-mail: journals@iiar-anticancer.org. Web: www.iiar-anticancer.org; www.iiarjournals.org

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 8, 2011.

Antagoras Agrobusiness, LLC., St. Louis, MO, U.S.A.
 Association pour la Recherche sur le Cancer, France

Biomedical Research Council of Singapore

Compagnia di San Paolo, Turin, Italy
 Computer Learning Research Centre, London, U.K.

Eli Lilly, Singapore

French National Cancer Institute (INCa), Boulogne-
 Billancourt, France
 Fundación Del Complejo Hospitalario Universitario A
 Coruña (CHUAC), Spain

Helen Rollason Cance Charity, Essex, U.K.
 Henry M. Jackson Foundation, Bethesda, MD, U.S.A.

INSERM, Paoli-Calmettes Institute, Marseille, France
 International Medical University (IMU), Malaysia
 Irish Cancer Research Board

Japan Society for the Promotion of Science
 Japan Society for the Promotion of Science, Tokyo, Japan

La Ligue Nationale Française de Lutte Contre le Cancer,
 France

Malaysian Palm Oil Board (MPOB), Malaysia

National Cancer Institute (NCI), National Institutes of
 Health (NIH), Bethesda, MD, U.S.A.

National Heart, Lung, and Blood Institute (NHLBI),
 Bethesda, MD, U.S.A.

National Institute of Food and Agriculture (NIFA),
 Washington, DC, U.S.A.

National Medical Research Council of Singapore
 National Natural Science Foundation of China (NSFC)
 National Science Council, Taiwan, R.O.C.

Research Committee of the Royal College of Surgeons in
 Ireland

Research Support Foundation of The University of
 Tokushima, Japan

Royal Holloway, University of London, U.K.

RTN EpiPlast Carcinoma, Sweden

Susan G. Komen Breast Cancer Foundation, TX, U.S.A.

Swedish Cancer Research Foundation

Swedish Institute

Swedish Research Council

TAIHO Pharmaceutical co., LTD., Osaka, Japan

Terry Fox Cancer Research Foundation, China Medical
 University Hospital, Taichung, Taiwan, R.O.C.

UCLH/UCL Comprehensive Biomedical Research Centre,
 London, U.K.

University of Reading, U.K.

US Military Cancer Institute

Contents, Volume 8, 2011

Number 1

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteomic Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALLDRIDGE, S. SOUCHELNYTSKYI (<i>Stockholm; Uppsala, Sweden; Chelmsford, UK; Olsztyn, Poland; Gold Coast, Qld, Australia</i>).....	1
<i>BRAF</i> p.Val600Glu (V600E) Somatic Mutation Is Mainly Associated with MSS Phenotype in Metastatic Colorectal Cancer. J. QIU, M. COMPAGNONE, S. LAIBE, A. LAGARDE, A. GONCALVES, O. TURRINI, L. XERRI, G. MONGES, S. OLSCHWANG (<i>Marseille, France; Suzhou, China</i>)	15
Tocotrienol-treated MCF-7 Human Breast Cancer Cells Show Downregulation of API5 and Up-regulation of MIG6 Genes. P. RAMDAS, M. RAJIHUZZAMAN, S.D. VEERASENAN, K.R. SELVADURAY, K. NESARETNAM, A.K. RADHAKRISHNAN (<i>Kuala Lumpur; Kajang, Selangor, Malaysia</i>)	19
Ionizing Radiation Affects Epidermal Growth Factor Receptor Signalling and Metalloproteinase Secretion in Glioma Cells. M. MARTINOU, E. GIANNOPOULOU, G. MALATARA, A.A. ARGYRIOU, H.P. KALOFONOS, D. KARDAMAKIS (<i>Patras, Greece</i>)	33
Parthenolide, An NF- κ B Inhibitor, Suppresses Tumor Growth and Enhances Response to Chemotherapy in Gastric Cancer. I. SOHMA, Y. FUJIWARA, Y. SUGITA, A. YOSHIOKA, M. SHIRAKAWA, J.-H. MOON, S. TAKIGUCHI, H. MIYATA, M. YAMASAKI, M. MORI, Y. DOKI (<i>Osaka, Japan</i>)	39

Number 2

* Review: Intracellular Proteins Displayed on the Surface of Tumor Cells as Targets for Therapeutic Intervention with Antibody-related Agents. U.H. WEIDLE, D. MAISEL, S. KLOSTERMANN, C. SCHILLER, E.H. WEISS (<i>Penzberg; Munich, Germany</i>)	49
New Gene Groups Associated with Dissimilar Osteoblastic Differentiation Are Linked to Osteosarcomagenesis. F. LUK, Y. YU, H.-T. DONG, W.R. WALSH, J.-L. YANG (<i>Sydney, NSW, Australia</i>).....	65
Small Molecule Inhibition of Cytoskeletal Dynamics in Melanoma Tumors Results in Altered Transcriptional Expression Patterns of Key Genes Involved in Tumor Initiation and Progression. C. SPENCER, J. MONTALVO, S.R. MCLAUGHLIN, B.A. BRYAN (<i>Worcester, MA, USA</i>).....	77
Gene Expression Profile Can Predict Pathological Response to Preoperative Chemoradiotherapy in Rectal Cancer. M. NISHIOKA, M. SHIMADA, N. KURITA, T. IWATA, S. MORIMOTO, K. YOSHIKAWA, J. HIGASHIJIMA, T. MIYATANI (<i>Tokushima, Japan</i>).....	87
Expression of Notch1 to -4 and their Ligands in Renal Cell Carcinoma: A Tissue Microarray Study. L.M. ANTÓN APARICIO, V. MEDINA VILLAAMIL, G. APARICIO GALLEGO, I. SANTAMARINA CAÍNZOS, R. GARCÍA CAMPELO, L. VALBUENA RUBIRA, S. VÁZQUEZ ESTÉVEZ, L. LEÓN MATEOS, J. L. FIRVIDA PEREZ, M. RAMOS VÁZQUEZ, O. FERNÁNDEZ CALVO, M. VICTORIA BOLÓS (<i>A Coruña; Lugo; Santiago de Compostela; Ourense; Madrid, Spain</i>)	93
Erratum	103

* Review (page 49)

Number 3	105
Conservation of Multifunctional Ribosomal Protein Metallopanstimulin-1 (RPS27) through Complex Evolution Demonstrates its Key Role in Growth Regulation in <i>Archaea</i> , Eukaryotic Cells, DNA Repair, Translation and Viral Replication. J. ALBERTO FERNANDEZ-POL (<i>Chesterfield, MO, USA</i>)	127
Tissue Microarray Analysis of Topoisomerase II α Protein in Gastric Adenocarcinomas: Histogenetic and Prognostic Implications. G. WANG, H. HUANG, J. GAO, P. CHEN, W. YOU, B. WU, M. WANG (<i>Beijing, P.R. China; Baltimore, MD, USA</i>)	135
Extraordinary Response to Erlotinib Therapy in a Patient with Lung Adenocarcinoma Exhibiting <i>KRAS</i> Mutation and <i>EGFR</i> Amplification. J. KREJCI, M. PESEK, P. GROSSMANN, M. KREJCI, J. RICAR, L. BENESOVA, M. MINARIK (<i>Pilsen; Prague, Czech Republic</i>)	139
<i>SOX2</i> Expression and Amplification in Gliomas and Glioma Cell Lines. L. ANNOVAZZI, M. MELLAI, V. CALDERA, G. VALENTE, D. SCHIFFER (<i>Vercelli; Novara, Italy</i>)	149
Analysis of <i>APC</i> Allelic Imbalance/Loss of Heterozygosity and <i>APC</i> Protein Expression in Cutaneous Squamous Cell Carcinomas. S.E. GRAY, E.W. KAY, M. LEADER, M. MABRUK (<i>Dublin, Ireland; Bandar Seri Bagawan, Brunei Darussalam, Ireland</i>)	157
Errata	159
 Number 4	 173
* Review: Synthetic Lethality-based Targets for Discovery of New Cancer Therapeutics. U.H. WEIDLE, D. MAISEL, D. EICK (<i>Penzberg; Munich, Germany</i>)	185
Therapy-, Gender- and Race-specific microRNA Markers, Target Genes and Networks Related to Glioblastoma Recurrence and Survival. K.R. DELFINO, N.V.L. SERÃO, B.R. SOUTHEY, S.L. RODRIGUEZ-ZAS (<i>Urbana, IL, USA</i>)	195
A Paradigm Shift in EPH Receptor Interaction: Biological Relevance of EPHB6 Interaction with EPHA2 and EPHB2 in Breast Carcinoma Cell Lines. B.P. FOX, R.P. KANDPAL (<i>Pomona, CA, USA</i>)	199
mRNA Expression of the Putative Antimetastatic Gene <i>BRMS1</i> and of Apoptosis-related Genes in Breast Cancer. J. SCHNEIDER, F. GÓMEZ-ESQUER, G. DÍAZ-GIL, R. TORREJÓN, M. POLLÁN (<i>Santander; Alcorcón; Sevilla; Madrid, Spain</i>)	211
Gene Expression Profiling and its Utility in Prediction of Local Relapse after Breast-conserving Therapy in Early Breast Cancer. R. SABATIER, P. FINETTI, N. CERVERA, A. TALLET, M. BENCHALAL, G. HOUVENAEHEL, J. JACQUEMIER, D. BIRNBAUM, F. BERTUCCI (<i>Marseille, Rennes, France</i>)	227
* Review (page 159)	227
 Number 5	
* Review: Differential Splicing Generates New Transmembrane Receptor and Extracellular Matrix-related Targets for Antibody-based Therapy of Cancer. U.H. WEIDLE, D. MAISEL, S. KLOSTERMANN, E.H. WEISS, M. SCHMITT (<i>Penzberg; Planegg-Martinsried; Munich, Germany</i>)	235
	319

Restoration of Senescence in Breast and Ovarian Cancer Cells Following the Transfer of the YAC Carrying SEN6A Gene Located at 6q16.3. N.S. RANE, A.K. SANDHU, V.S. ZHAWAR, G. KAUR, N.C. POPESCU, R.P. KANDPAL, M. JHANWAR-UNIYAL, R.S. ATHWAL (<i>Philadelphia, PA; Bethesda, MD; Pomona, CA; Valhalla, NY, USA</i>)	245
Aberrant Expression of Chromogranin A, miR-146a, and miR-146b-5p in Prostate Structures with Focally Disrupted Basal Cell Layers: An Early Sign of Invasion and Hormone-refractory Cancer? Y.G. MAN, S.W. FU, A.J. LIU, A. STOJADINOVIC, M.J. IZADJOO, L. CHEN, W.A. GARDNER (<i>Gaithersburg, MD; Washington, DC, USA; Beijing, PR China</i>)	251
Timing of Ganciclovir Administration in Glioma Gene Therapy Using HSVtk Gene-transduced Mesenchymal Stem Cells. S. AMANO, C. GU, S. KOIZUMI, T. TOKUYAMA, H. NAMBA (<i>Hamamatsu, Japan; Shenyang, PR China</i>)	255
Association of Alpha B-Crystallin (CRYAB) Genotypes with Breast Cancer Susceptibility in Taiwan. C.-H. SU, L.-C. LIU, Y.-H. HSIEH, H.-C. WANG, C.-W. TSAI, W.-S. CHANG, C.-Y. HO, C.-I. WU, C.-H. LIN, H.-Y. LANE, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	261
Gemcitabine and Platinum Pathway Pharmacogenetics in Asian Breast Cancer Patients. A.L.-A. WONG, H.-L. YAP, W.-L. YEO, R. SOONG, S.-S. NG, L.-Z. WANG, M.T. CORDERO, W.-P. YONG, B.-C. GOH, S.-C. LEE (<i>Singapore, Singapore</i>).....	263
Announcements.....	289
* Review (page 211)	307
	311

Number 6

* Review: The Cancer Biomarker Osteopontin: Combination with Other Markers. G.F. WEBER (<i>Cincinnati, OH, USA</i>).....	
Early Detection of Ovarian Cancer in Samples Pre-Diagnosis Using CA125 and MALDI-MS Peaks. J.F. TIMMS, U. MENON, D. DEVETJAROV, A. TISS, S. CAMUZEUX, K. MCCURRIE, I. NOURETDINOV, B. BURFORD, C. SMITH, A. GENTRY-MAHARAJ, R. HALLETT, J. FORD, Z. LUO, V. VOVK, A. GAMMERMAN, R. CRAMER, I. JACOBS (<i>London; Egham, Surrey; Reading, Berkshire, UK</i>)	
The Role of Metalloendopeptidases in Oropharyngeal Carcinomas Assessed by Tissue Microarray. D.A. RIBEIRO, F.D. NASCIMENTO, A.C.C. FRACALLOSSI, J. NOGUTI, C.T.F. OSHIMA, S.S.M. IHARA, M.F. FRANCO (<i>Sao Paulo, Brazil</i>)	
Index 2011.....	
* Review (page 263)	

Subject Index

(Figures refer to page numbers)

- Actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleolin, nucleosomes, tumor-specific antigens, vimentin, review, 49
- Adenocarcinoma, NSCLC, erlotinib, KRAS mutation, EGFR amplification, 135
- Allelic imbalance/loss of heterozygosity, APC, cutaneous squamous cell carcinoma, 149
- Alpha B-crystallin, polymorphism, breast cancer, carcinogenesis, 251
- Amplification, SOX2, distribution, gliomas, stem cells, 139
- Angiogenesis, constitutive signalling, exon deletion and insertion, hallmarks of cancer, immunocytokines, neo-epitope(s), tumor-specific targets, tumor targeting, therapeutic window, review, 211
- Anti-EGFR response, metastasis, BRAF gene, somatic mutation, colorectal cancer, microsatellites, 15
- APC, allelic imbalance/loss of heterozygosity, cutaneous squamous cell carcinoma, 149
- API5, vitamin E, tocotrienols, gene expression, apoptosis inhibitors, EGFR inhibitor, breast cancer, MIG6, 19
- Apoptosis inhibitors, vitamin E, tocotrienols, gene expression, EGFR inhibitor, breast cancer, API5, MIG6, 19
- Apoptosis, cancer, breast, BRMS1, RNA binding motif, 195
- Basal cells, prostate cancer, tumor progression, chromogranin A, miRNA, 235
- Biomarker, cancer, osteopontin, diagnosis, prognosis, review, 263
- Biomarkers, glioblastoma, microRNA, hazard, clinical cohort, gender, race, 173
- Biomarkers, MALDI-MS serum profiling, ovarian cancer, early diagnosis, CA125, connective tissue-activating peptide III, CTAPIII, platelet factor 4, PF4, 289
- BRAF gene, metastasis, anti-EGFR response, somatic mutation, colorectal cancer, microsatellites, 15
- Breast cancer, alpha B-crystallin, polymorphism, carcinogenesis, 251
- Breast cancer, cell senescence, SEN6A gene, ovarian cancer, 227
- Breast cancer, EPH receptors, EPHB6, EPHA2, EPHB2, EPHA10, protein-protein interaction, co-immunoprecipitation, tumor suppressor, 185
- Breast cancer, gemcitabine, carboplatin, pharmacogenetics, genetic polymorphisms, 255
- Breast cancer, local relapse, gene expression profiling, 199
- Breast cancer, proteomics, signalling, meta-data analysis, 1
- Breast cancer, vitamin E, tocotrienols, gene expression, apoptosis inhibitors, EGFR inhibitor, API5, MIG6, 19
- Breast, cancer, apoptosis, BRMS1, RNA binding motif, 195
- BRMS1, cancer, breast, apoptosis, RNA binding motif, 195
- CA125, MALDI-MS serum profiling, ovarian cancer, biomarkers, early diagnosis, connective tissue-activating peptide III, CTAPIII, platelet factor 4, PF4, 289
- Cancer, biomarker, osteopontin, diagnosis, prognosis, review, 263
- Cancer, breast, apoptosis, BRMS1, RNA binding motif, 195
- Carboplatin, gemcitabine, pharmacogenetics, genetic polymorphisms, breast cancer, 255
- Carcinogenesis, alpha B-crystallin, polymorphism, breast cancer, 251
- Cell senescence, SEN6A gene, breast cancer, ovarian cancer, 227
- Chemoradiotherapy, tailored therapy, focused DNA microarray, S-1, rectal cancer, gene expression profiling, 87
- Chemotherapy, parthenolide, NF-kappaB, gastric cancer, peritoneal dissemination, microarray, 39
- Chorioallantoic membrane tumor assay, melanoma, Rho kinase, cytoskeleton, microarray, tumor initiation, tumor progression, 77
- Chromogranin A, prostate cancer, tumor progression, basal cells, miRNA, 235
- Clinical cohort, glioblastoma, microRNA, biomarkers, hazard, gender, race, 173
- Co-immunoprecipitation, EPH receptors, EPHB6, EPHA2, EPHB2, EPHA10, protein-protein interaction, breast cancer, tumor suppressor, 185
- Colorectal cancer, metastasis, anti-EGFR response, BRAF gene, somatic mutation, microsatellites, 15
- Connective tissue-activating peptide III, MALDI-MS serum profiling, ovarian cancer, biomarkers, early diagnosis, CA125, CTAPIII, platelet factor 4, PF4, 289
- Constitutive signalling, angiogenesis, exon deletion and insertion, hallmarks of cancer, immunocytokines, neo-epitope(s), tumor-specific targets, tumor targeting, therapeutic window, review, 211
- CTAPIII, MALDI-MS serum profiling, ovarian cancer, biomarkers, early diagnosis, CA125, connective tissue-activating peptide III, platelet factor 4, PF4, 289
- Cutaneous squamous cell carcinoma, allelic imbalance/loss of heterozygosity, APC, 149
- Cytokeratin(s), actin, estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleolin, nucleosomes, tumor-specific antigens, vimentin, review, 49
- Cytoskeleton, melanoma, chorioallantoic membrane tumor assay, Rho kinase, microarray, tumor initiation, tumor progression, 77
- Diagnosis, biomarker, cancer, osteopontin, prognosis, review, 263
- Disrupted osteoblast differentiation, gene expression, osteosarcoma, osteogenic induction, 65
- Distribution, SOX2, amplification, gliomas, stem cells, 139
- DNA repair, oncogenes, poly(ADP) ribose polymerase, protein kinase networks, tumor suppressor genes, review, 159
- Early diagnosis, MALDI-MS serum profiling, ovarian cancer, biomarkers, CA125, connective tissue-activating peptide III, CTAPIII, platelet factor 4, PF4, 289

- EGFR amplification, NSCLC, adenocarcinoma, erlotinib, KRAS mutation, 135
- EGFR inhibitor, vitamin E, tocotrienols, gene expression, apoptosis inhibitors, breast cancer, API5, MIG6, 19
- EGFR, gliomas, ionizing radiation, MMPs, 33
- EPH receptors, EPHB6, EPHA2, EPHB2, EPHA10, protein-protein interaction, co-immunoprecipitation, breast cancer, tumor suppressor, 185
- EPHA10, EPH receptors, EPHB6, EPHA2, EPHB2, protein-protein interaction, co-immunoprecipitation, breast cancer, tumor suppressor, 185
- EPHA2, EPH receptors, EPHB6, EPHB2, EPHA10, protein-protein interaction, co-immunoprecipitation, breast cancer, tumor suppressor, 185
- EPHB2, EPH receptors, EPHB6, EPHA2, EPHA10, protein-protein interaction, co-immunoprecipitation, breast cancer, tumor suppressor, 185
- EPHB6, EPH receptors, EPHA2, EPHB2, EPHA10, protein-protein interaction, co-immunoprecipitation, breast cancer, tumor suppressor, 185
- Erlotinib, NSCLC, adenocarcinoma, KRAS mutation, EGFR amplification, 135
- Estrogen receptor, actin, cytokeratin(s), feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleolin, nucleosomes, tumor-specific antigens, vimentin, review, 49
- Exon deletion and insertion, angiogenesis, constitutive signalling, hallmarks of cancer, immunocytokines, neo-epitope(s), tumor-specific targets, tumor targeting, therapeutic window, review, 211
- Feto-acinar pancreatic protein, actin, cytokeratin(s), estrogen receptor, glucose-related protein 78, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleolin, nucleosomes, tumor-specific antigens, vimentin, review, 49
- Focused DNA microarray, tailored therapy, S-1, chemoradiotherapy, rectal cancer, gene expression profiling, 87
- Ganciclovir, mesenchymal stem cells, glioma, suicide gene therapy, herpes simplex virus thymidine kinase, 245
- Gastric cancer, parthenolide, NF-kappaB, peritoneal dissemination, microarray, chemotherapy, 39
- Gastric carcinoma, topoisomerase II α , tissue microarray, prognosis, 127
- Gemcitabine, carboplatin, pharmacogenetics, genetic polymorphisms, breast cancer, 255
- Gender, glioblastoma, microRNA, biomarkers, hazard, clinical cohort, race, 173
- Gene expression profiling, breast cancer, local relapse, 199
- Gene expression profiling, tailored therapy, focused DNA microarray, S-1, chemoradiotherapy, rectal cancer, 87
- Gene expression, osteosarcoma, disrupted osteoblast differentiation, osteogenic induction, 65
- Gene expression, vitamin E, tocotrienols, apoptosis inhibitors, EGFR inhibitor, breast cancer, API5, MIG6, 19
- Genetic polymorphisms, gemcitabine, carboplatin, pharmacogenetics, breast cancer, 255
- Glioblastoma, microRNA, biomarkers, hazard, clinical cohort, gender, race, 173
- Glioma, mesenchymal stem cells, suicide gene therapy, ganciclovir, herpes simplex virus thymidine kinase, 245
- Gliomas, ionizing radiation, EGFR, MMPs, 33
- Gliomas, SOX2, distribution, amplification, stem cells, 139
- Glucose-related protein 78, actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleolin, nucleosomes, tumor-specific antigens, vimentin, review, 49
- Hallmarks of cancer, angiogenesis, constitutive signalling, exon deletion and insertion, immunocytokines, neo-epitope(s), tumor-specific targets, tumor targeting, therapeutic window, review, 211
- Hazard, glioblastoma, microRNA, biomarkers, clinical cohort, gender, race, 173
- Heat-shock proteins 70 and 90, actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, Ingenuity Pathway Analysis, IPA, nucleolin, nucleosomes, tumor-specific antigens, vimentin, review, 49
- Herpes simplex virus thymidine kinase, mesenchymal stem cells, glioma, suicide gene therapy, ganciclovir, 245
- Immunocytokines, angiogenesis, constitutive signalling, exon deletion and insertion, hallmarks of cancer, neo-epitope(s), tumor-specific targets, tumor targeting, therapeutic window, review, 211
- Immunohistochemistry, notch, notch ligands, renal cancer biomarkers, tissue array, 93
- Ingenuity Pathway Analysis IPA, actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, nucleolin, nucleosomes, tumor-specific antigens, vimentin, review, 49
- Ionizing radiation, gliomas, EGFR, MMPs, 33
- IPA, Ingenuity Pathway Analysis, actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, nucleolin, nucleosomes, tumor-specific antigens, vimentin, review, 49
- KRAS mutation, NSCLC, adenocarcinoma, erlotinib, EGFR amplification, 135
- Local relapse, breast cancer, gene expression profiling, 199
- MALDI-MS serum profiling, ovarian cancer, biomarkers, early diagnosis, CA125, connective tissue-activating peptide III, CTAPIII, platelet factor 4, PF4, 289
- Melanoma, chorioallantoic membrane tumor assay, Rho kinase, cytoskeleton, microarray, tumor initiation, tumor progression, 77
- Mesenchymal stem cells, glioma, suicide gene therapy, ganciclovir, herpes simplex virus thymidine kinase, 245
- Meta-data analysis, proteomics, breast cancer, signalling, 1
- Metalloendopeptidases, squamous cell carcinomas, tissue microarray, 307
- Metallopanstimulin-1, RPMPS-1/RPS27, p53, RP, ribosomal protein, 105
- Metastasis, anti-EGFR response, BRAF gene, somatic mutation, colorectal cancer, microsatellites, 15
- Microarray, melanoma, chorioallantoic membrane tumor assay, Rho kinase, cytoskeleton, tumor initiation, tumor progression, 77
- Microarray, parthenolide, NF-kappaB, gastric cancer, peritoneal dissemination, chemotherapy, 39

- MicroRNA, glioblastoma, biomarkers, hazard, clinical cohort, gender, race, 173
- Microsatellites, metastasis, anti-EGFR response, BRAF gene, somatic mutation, colorectal cancer, 15
- MIG6, vitamin E, tocotrienols, gene expression, apoptosis inhibitors, EGFR inhibitor, breast cancer, API5, 19
- MiRNA, prostate cancer, tumor progression, chromogranin A, basal cells, 235
- MMPs, gliomas, ionizing radiation, EGFR, 33
- Neo-epitope(s), angiogenesis, constitutive signalling, exon deletion and insertion, hallmarks of cancer, immunocytokines, tumor-specific targets, tumor targeting, therapeutic window, review, 211
- NF-kappaB, parthenolide, gastric cancer, peritoneal dissemination, microarray, chemotherapy, 39
- Notch ligands, notch, immunohistochemistry, renal cancer biomarkers, tissue array, 93
- Notch, notch ligands, immunohistochemistry, renal cancer biomarkers, tissue array, 93
- NSCLC, adenocarcinoma, erlotinib, KRAS mutation, EGFR amplification, 135
- Nucleolin, actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleosomes, tumor-specific antigens, vimentin, review, 49
- Nucleosomes, actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleolin, tumor-specific antigens, vimentin, review, 49
- Oncogenes, DNA repair, poly(ADP) ribose polymerase, protein kinase networks, tumor suppressor genes, review, 159
- Osteogenic induction, gene expression, osteosarcoma, disrupted osteoblast differentiation, 65
- Osteopontin, biomarker, cancer, diagnosis, prognosis, review, 263
- Osteosarcoma, gene expression, disrupted osteoblast differentiation, osteogenic induction, 65
- Ovarian cancer, cell senescence, SEN6A gene, breast cancer, 227
- Ovarian cancer, MALDI-MS serum profiling, biomarkers, early diagnosis, CA125, connective tissue-activating peptide III, CTAPIII, platelet factor 4, PF4, 289
- P53, metallopanstimulin-1, RPMPS-1/RPS27, RP, ribosomal protein, 105
- Parthenolide, NF-kappaB, gastric cancer, peritoneal dissemination, microarray, chemotherapy, 39
- Peritoneal dissemination, parthenolide, NF-kappaB, gastric cancer, microarray, chemotherapy, 39
- PF4, MALDI-MS serum profiling, ovarian cancer, biomarkers, early diagnosis, CA125, connective tissue-activating peptide III, CTAPIII, platelet factor 4, 289
- Pharmacogenetics, gemcitabine, carboplatin, genetic polymorphisms, breast cancer, 255
- Platelet factor 4, MALDI-MS serum profiling, ovarian cancer, biomarkers, early diagnosis, CA125, connective tissue-activating peptide III, CTAPIII, PF4, 289
- Poly(ADP) ribose polymerase, DNA repair, oncogenes, protein kinase networks, tumor suppressor genes, review, 159
- Polymorphism, alpha B-crystallin, breast cancer, carcinogenesis, 251
- Prognosis, biomarker, cancer, osteopontin, diagnosis, review, 263
- Prognosis, gastric carcinoma, topoisomerase II α , tissue microarray, 127
- Prostate cancer, tumor progression, chromogranin A, basal cells, miRNA, 235
- Protein kinase networks, DNA repair, oncogenes, poly(ADP) ribose polymerase, tumor suppressor genes, review, 159
- Protein-protein interaction, EPH receptors, EPHB6, EPHA2, EPHB2, EPHA10, co-immunoprecipitation, breast cancer, tumor suppressor, 185
- Proteomics, breast cancer, signalling, meta-data analysis, 1
- Race, glioblastoma, microRNA, biomarkers, hazard, clinical cohort, gender, 173
- Rectal cancer, tailored therapy, focused DNA microarray, S-1, chemoradiotherapy, gene expression profiling, 87
- Renal cancer biomarkers, notch, notch ligands, immunohistochemistry, tissue array, 93
- Review, actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleolin, nucleosomes, tumor-specific antigens, vimentin, 49
- Review, angiogenesis, constitutive signalling, exon deletion and insertion, hallmarks of cancer, immunocytokines, neo-epitope(s), tumor-specific targets, tumor targeting, therapeutic window, 211
- Review, biomarker, cancer, osteopontin, diagnosis, prognosis, 263
- Review, DNA repair, oncogenes, poly(ADP) ribose polymerase, protein kinase networks, tumor suppressor genes, 159
- Rho kinase, melanoma, chorioallantoic membrane tumor assay, cytoskeleton, microarray, tumor initiation, tumor progression, 77
- Ribosomal protein, metallopanstimulin-1, RPMPS-1/RPS27, p53, RP, 105
- RNA binding motif, cancer, breast, apoptosis, BRMS1, 195
- RP, metallopanstimulin-1, RPMPS-1/RPS27, p53, ribosomal protein, 105
- RPMPS-1/RPS27, metallopanstimulin-1, p53, RP, ribosomal protein, 105
- S-1, tailored therapy, focused DNA microarray, chemoradiotherapy, rectal cancer, gene expression profiling, 87
- SEN6A gene, cell senescence, breast cancer, ovarian cancer, 227
- Signalling, proteomics, breast cancer, meta-data analysis, 1
- Somatic mutation, metastasis, anti-EGFR response, BRAF gene, colorectal cancer, microsatellites, 15
- SOX2, distribution, amplification, gliomas, stem cells, 139
- Squamous cell carcinomas, tissue microarray, metalloendopeptidases, 307
- Stem cells, SOX2, distribution, amplification, gliomas, 139
- Suicide gene therapy, mesenchymal stem cells, glioma, ganciclovir, herpes simplex virus thymidine kinase, 245

- Tailored therapy, focused DNA microarray, S-1, chemoradiotherapy, rectal cancer, gene expression profiling, 87
- Therapeutic window, angiogenesis, constitutive signalling, exon deletion and insertion, hallmarks of cancer, immunocytokines, neo-epitope(s), tumor-specific targets, tumor targeting, review, 211
- Tissue array, notch, notch ligands, immunohistochemistry, renal cancer biomarkers, 93
- Tissue microarray, gastric carcinoma, topoisomerase II α , prognosis, 127
- Tissue microarray, squamous cell carcinomas, metalloendopeptidases, 307
- Tocotrienols, vitamin E, gene expression, apoptosis inhibitors, EGFR inhibitor, breast cancer, API5, MIG6, 19
- Topoisomerase II α , gastric carcinoma, tissue microarray, prognosis, 127
- Tumor initiation, melanoma, chorioallantoic membrane tumor assay, Rho kinase, cytoskeleton, microarray, tumor progression, 77
- Tumor progression, melanoma, chorioallantoic membrane tumor assay, Rho kinase, cytoskeleton, microarray, tumor initiation, 77
- Tumor progression, prostate cancer, chromogranin A, basal cells, miRNA, 235
- Tumor suppressor genes, DNA repair, oncogenes, poly(ADP) ribose polymerase, protein kinase networks, review, 159
- Tumor suppressor, EPH receptors, EPHB6, EPHA2, EPHB2, EPHA10, protein-protein interaction, co-immunoprecipitation, breast cancer, 185
- Tumor targeting, angiogenesis, constitutive signalling, exon deletion and insertion, hallmarks of cancer, immunocytokines, neo-epitope(s), tumor-specific targets, therapeutic window, review, 211
- Tumor-specific antigens, actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleolin, nucleosomes, vimentin, review, 49
- Tumor-specific targets, angiogenesis, constitutive signalling, exon deletion and insertion, hallmarks of cancer, immunocytokines, neo-epitope(s), tumor targeting, therapeutic window, review, 211
- Vimentin, actin, cytokeratin(s), estrogen receptor, feto-acinar pancreatic protein, glucose-related protein 78, heat-shock proteins 70 and 90, Ingenuity Pathway Analysis, IPA, nucleolin, nucleosomes, tumor-specific antigens, review, 49
- Vitamin E, tocotrienols, gene expression, apoptosis inhibitors, EGFR inhibitor, breast cancer, API5, MIG6, 19

Authors Index

(Figures refer to page numbers)

- Alldridge L, 1
 Amano S, 245
 Annovazzi L, 139
 Aparicio LM, 93
 Argyriou AA, 33
 Athwal RS, 227
 Bau D-T, 251
 Benchalal M, 199
 Benesova L, 135
 Bertucci F, 199
 Birnbaum D, 199
 Bolós MV, 93
 Bryan BA, 77
 Burford B, 289
 Caínzos IS, 93
 Caldera V, 139
 Calvo OF, 93
 Campelo RG, 93
 Camuzeaux S, 289
 Cervera N, 199
 Chang W-S, 251
 Chen L, 235
 Chen P, 127
 Compagnone M, 15
 Cordero MT, 255
 Cramer R, 289
 Delfino KR, 173
 Devetyarov D, 289
 Díaz-Gil G, 195
 Doki Y, 39
 Dong H-T, 65
 Eick D, 159
 Estévez SV, 93
 Fernandez-Pol JA, 105
 Finetti P, 199
 Ford J, 289
 Fox BP, 185
 Fracalossi ACC, 307
 Franco MF, 307
 Fu SW, 235
 Fujiwara Y, 39
 Gallego GA, 93
 Gammerman A, 289
 Gao J, 127
 Gardner WA, 235
 Gentry-Maharaj A, 289
 Giannopoulou E, 33
 Goh B-C, 255
 Gómez-Esquer F, 195
 Goncalves A, 15
 Gray SE, 149
 Greenwood C, 1
 Grossmann P, 135
 Gu C, 245
 Hallett R, 289
 Hellman U, 1
 Higashijima J, 87
 Ho C-Y, 251
 Houvenaeghel G, 199
 Hsieh Y-H, 251
 Huang H, 127
 Ihara SSM, 307
 Iwata T, 87
 Izadjoo MJ, 235
 Jacobs I, 289
 Jacquemier J, 199
 Jhanwar-Uniyal M, 227
 Kalofonos HP, 33
 Kandpal RP, 185, 227
 Kardamakis D, 33
 Kaur G, 227
 Kay EW, 149
 Klostermann S, 49, 211
 Koizumi S, 245
 Krejci J, 135
 Krejci M, 135
 Kurita N, 87
 Lagarde A, 15
 Laibe S, 15
 Lane H-Y, 251
 Leader M, 149
 Lee S- C, 255
 Lewandowska A, 1
 Lin C-H, 251
 Liu AJ, 235
 Liu L-C, 251
 Luk F, 65
 Luo Z, 289
 Mabruk M, 149
 Maisel D, 49, 159, 211
 Malatara G, 33
 Man YG, 235
 Martinou M, 33
 Mateos LL, 93
 McCurrie K, 289
 McLaughlin SR, 77
 Mellai M, 139
 Menon U, 289
 Minarik M, 135
 Miyata H, 39
 Miyatani T, 87
 Monges G, 15
 Montalvo J, 77
 Moon J-H, 39
 Mori M, 39
 Morimoto S, 87
 Namba H, 245
 Nascimento FD, 307
 Nesaretnam K, 19
 Ng S-S, 255
 Nishioka M, 87
 Noguti J, 307
 Nouretdinov I, 289
 Olschwang S, 15
 Oshima CTF, 307
 Perez JL, 93
 Pesek M, 135
 Pollán M, 195
 Popescu NC, 227
 Qiu J, 15
 Radhakrishnan AK, 19
 Rajihuzzaman M, 19
 Ramdas P, 19
 Rane NS, 227
 Ribeiro DA, 307
 Ricar J, 135
 Rodriguez-Zas SL, 173
 Rubira LV, 93
 Sabatier R, 199
 Sandhu AK, 227
 Schiffer D, 139
 Schiller C, 49
 Schmitt M, 211
 Schneider J, 195
 Selvaduray KR, 19
 Serão NVL, 173
 Shimada M, 87
 Shirakawa M, 39
 Smith C, 289
 Sohma I, 39
 Soong R, 255
 Souchelnytskyi S, 1
 Southey BR, 173
 Spencer C, 77
 Stojadinovic A, 235
 Su C-H, 251
 Sugita Y, 39
 Takiguchi S, 39
 Tallet A, 199
 Timms JF, 289
 Tiss A, 289
 Tokuyama T, 245
 Torrejón R, 195
 Tsai C-W, 251
 Turrini O, 15
 Valente G, 139
 Vázquez MR, 93
 Veerasenan SD, 19
 Villaamil VM, 93
 Vovk V, 289
 Walsh WR, 65
 Wang G, 127
 Wang H-C, 251
 Wang L-Z, 255
 Wang M, 127
 Weber GF, 263
 Weidle UH, 49, 159, 211
 Weiss EH, 49, 211
 Wong AL-A, 255
 Wu B, 127
 Wu C-I, 251
 Xerri L, 15
 Yamasaki M, 39
 Yang J-L, 65
 Yap H-L, 255
 Yeo W-L, 255
 Yong W-P, 255
 Yoshikawa K, 87
 Yoshioka A, 39
 You W, 127
 Yu Y, 65
 Zakharchenko O, 1
 Zhawar VS, 227

Errata

Volume 7, No. 5, pages 246, 247, 248:

The last sentence of the legends of Figures 1, 2 and 3 should read:

The darker brown stain indicates a positive result.

Volume 8, No. 2, page 53:

The legend of Figure 4 should read:

Amino acid sequences of ER isoforms ER- α 66, ER- α 46 and ER- α 36. Sequences were derived from Swissprot ESR1_HUMAN (ER- α 66 and ER- α 46) and TrEMBL Q6MZZ9_HUMAN for ER- α 36. A discrepancy at residue #279 (Leu to Ile) was noted.

Volume 8, No. 2, page 54:

The legend of Figure 5 should read:

Amino acid sequences of BSDL and FAPP. BSDL sequence was derived from Swissprot CEL_HUMAN (phasing of tandem repeats was modified), FAPP sequence was derived from TrEMBL. Discrepancy at residue #599 (Gly to Asp) was noted, no signal sequence is displayed.

CANCER GENOMICS & PROTEOMICS supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR, Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit our websites: www.iiar-anticancer.org, www.cgp.iiarjournals.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: journals@iiar-anticancer.org (Editorial Office), editor@iiar-anticancer.org (Managing Editor).

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

Annual Subscription (print and online) Rates 2012:

Institutional subscription: Euro 800 per volume. Personal subscription: Euro 400 per volume. The above rates include: print and/or online subscriptions, rapid delivery and insurance. Additionally, 2012 subscribers have free online access to all previous volumes of CGP. Reduced subscription rates are offered to Authors. Please visit <http://cgp.iiarjournal.org> for further details.

Subscription orders can be placed at agencies, bookstores or directly with the Publisher. Cheques should be made payable to J.G. Delinassios, IIAR, Executive Publisher and should be sent to the Editorial Office of CGP. Please visit <http://cgp.iiarjournal.org> for further details. Previous volumes (2004-2011) are available at 50% discount.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Managing Editor, Athens, Greece, and should be sent to the Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.